Summary
The role of complement in the pathogenesis of diabetes was studied in 31 Type 1 (insulin-dependent) diabetic children by assaying serum islet cell surface antibody, C3, C4 and serum complement-dependent antibody-mediated cytotoxicity. Nine of 21 islet cell surface antibody-positive children were within 5 months of disease onset and showed significantly lower serum C3 and C4 levels than either 1 year later or the remainder of the islet cell surface antibody-positive children at 6–12 months after disease onset. The overall trend of all islet cell surface antibody-positive diabetic children within 1 year of disease onset was toward increased serum C3 and C4 levels as the disease progressed. Serum C4 concentration and complement-dependent antibody-mediated cytotoxicity which showed an initial negative correlation were uncorrelated 1 year later. Four children who were initially strongly islet cell surface antibody-positive but negative 1 year later also exhibited significantly higher (p<0.05) mean serum C4levels after 1 year. There was a significant decrease in complement-dependent antibody-mediated cytotoxicity when sera from the diabetic children were treated with either ethylene glycol tetra-acetic acid or ethylene diamine tetra-acetic acid. These data strongly suggest that complement-dependent antibody-mediated cytotoxicity induced by the classical complement pathway involving an islet cell surface antibody may play an important role in the pathogenesis of Type 1 diabetes.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Dobersen MJ, Scharff JE, Ginsberg-Fellner F, Notkins AL (1980) Cytotoxic autoantibodies to beta cells in the serum of patients with insulin-dependent diabetes mellitus. N Engl J Med 303: 1493–1498
Lernmark Å, Sehlin J, Taljedal I-B, Kromann H, Nerup J (1978) Possible toxic effects of normal and diabetic patient serum on pancreatic B cells. Diabetologia 14: 25–31
West CD, Davis NC, Forristal J, Herbst J, Spitzer R (1966) Antigenic determinants of human β1C- and β1G-globulins. J Immunol 96: 650–658
Lacy PE, Kostianovsky M (1967) Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16: 35–39
Meda P, Hooghe-Peters EL, Orci L (1980) Monolayer cultures of adult pancreatic islet cells on osmotically disrupted fibroblasts. Diabetes 29: 497–500
Yokota A (1987) Binding of anti-BSA antibody with cultured rat insulinoma cells. J Jap Diab Soc [Suppl 1] 30: 256
Soderstrum WK, Freedman ZR, Lernmark Å (1979) Complement-dependent cytotoxic islet cell surface antibodies in insulin-dependent diabetes. Diabetes 28: 397
Vergani D, Johnston C, B-Abdullah N, Barnett AH (1983) Low serum C4 concentrations: an inherited predisposition to insulin-dependent diabetes? Br Med J 286: 926–928
Dawkins RL, Uko G, Christiansen FT, Kay PH (1983) Low C4 concentrations in insulin-dependent diabetes mellitus. Br Med J 287: 839
Awdeh ZL, Ochs HD, Alper CA (1981) Genetic analysis of C4 deficiency. J Clin Invest 67: 260–263
Dawkins RL, Christiansen FT, Kay PH (1983) Disease associations with complotypes, supratypes and haprotypes. Immunol Rev 70: 5–22
Raum D, Awdeh ZL, Alper CA (1981) Bf types and mode of inheritance of insulin-dependent diabetes mellitus (IDDM). Immunogenetics 12: 59–74
Nakajima N, Kan K, Sugisaki T (1983) Clinical significance in measurement of total amount of C3 and native Cn4 in various disease. Clin Immunol 15: 497–504 (in Japanese)
Inai S, Hiramatsu S (1974) The estimation of the protein levels of complement components. Clin Pathol 22: 640–645 (in Japanese)
Maki S, Miyata H, Uraoka Y, Yoshioka K (1976) Renal diseases: movement of various components of serum complement. Clin Immunol 8: 743–754 (in Japanese)
Vialletes B, Lassmann V, Vague PH (1983) Diminution du taux sérique du composant C3du complement dans le diabète insulin-dependant recent. Diabete Metab 9: 66–68
Gewurz H, Pickering RJ, Mergenhagen SE (1968) The complement profile in acute glomerulonephritis, systemic lupus erythematosus and hypocomplementemic chronic glomerulonephritis. Int Arch Allergy Appol Immunol 34: 556–570
Kohler PF, Ten Bensel R (1969) Serial complement component alterations in acute glomerulonephritis and systemic lupus erythematosus. Clin Exp Immunol 4: 191–226
Petz LD, Sharp GC, Cooper NR (1971) Serum and cerebral spinal fluid complement and serum autoantibodies in systemic lupus erythematosus. Medicine 50: 259–275
Perrin LH, Lambert PH, Nydegger UE (1973) Quantitation of C3PA (Properdin Factor B) and other complement components in disease associated with a low C3 level. Clin Immunol Immunopathol 2: 16–27
Ruddy S, Gigli I, Austen KF (1972) The complement system of man. N Engl J Med 237: 592–646
Sundsmo JS, Papin RA, Wood L, Hirani S, Waldeck N, Buckingham B, Kershnar A, Ascher M, Charles MA (1985) Complement activation in Type 1 human diabetes. Clin Immunol Immunopathol 35: 211–225
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Okada, S., Sato, K., Miyai, Y. et al. Serum C3 and C4 levels and complement-dependent antibody-mediated cytotoxic activity of islet cell surface antibody in Type 1 (insulin-dependent) diabetic children. Diabetologia 30, 869–873 (1987). https://doi.org/10.1007/BF00274796
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00274796